Is there a role for natural desiccated thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a consecutive case series.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
19
09
2021
received:
10
08
2021
accepted:
06
10
2021
pubmed:
10
10
2021
medline:
1
1
2022
entrez:
9
10
2021
Statut:
ppublish
Résumé
Some levothyroxine unresponsive individuals with hypothyroidism are prescribed a natural desiccated thyroid (NDT) preparation such as Armour Thyroid The ThyPRO39 (thyroid symptomatology) and EQ-5D-5L-related QoL/EQ5D5L (generic QOL) questionnaires were administered to 31 consecutive patients who had been initiated on NDT, before initiating treatment/6 months later. There were 28 women and 3 men. The dose range of NDT was 60-180 mg daily. Age range was 26-77 years with length of time since diagnosis with hypothyroidism ranging from 2 to 40 years. One person discontinued the NDT because of lack of response; two because of cardiac symptoms. EQ-5D-5L utility increased from a mean (SD) of 0.214 (0.338) at baseline, to 0.606 (0.248) after 6 months; corresponding to a difference of 0.392 (95% CI 0.241-0.542), t = 6.82, P < .001. EQ-VAS scores increased from 33.4 (17.2) to 71.1 (17.5), a difference of 37.7 (95% CI 25.2-50.2), t = -4.9, P < .001. ThyPRO scores showed consistent fall across all domains with the composite QoL-impact Score improving from 68.3 (95% CI 60.9-75.7) to 25.2 (95% CI 18.7-31.7), a difference of 43.1 (95% CI 33-53.2) (t = 5.6, P < .001). Significant symptomatic benefit and improvement in QOL was experienced by people with a history of levothyroxine unresponsive hypothyroidism treated with NDT, suggesting the need for further evaluation of NDT in this context.
Substances chimiques
Triiodothyronine
06LU7C9H1V
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14967Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301-316.
Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577-585.
McAninch EA, Bianco AC. The history and future of treatment of hypothyroidism. Ann Intern Med. 2016;164:50-56.
Smith RN, Taylor SA, Massey JC. Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. Br Med J. 1970;17(4):145-148.
Gaby AR. Sub-laboratory hypothyroidism and the empirical use of Armour thyroid. Altern Med Rev. 2004;9:157-179.
Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017;55:6-18.
Idrees T, Palmer S, Maciel RMB, Bianco AC. Liothyronine and desiccated thyroid extract in the treatment of hypothyroidism. Thyroid. 2020;3:1399-1413.
NICE. https://www.nice.org.uk/guidance/indevelopment/gid-ng10074 Accessed November 2, 2020.
Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98:1982-1990.
Tariq A, Wert Y, Cheriyath P, Joshi R. Effects of long-term combination LT4 and LT3 therapy for improving hypothyroidism and overall quality of life. South Med J. 2018;111:363-369.
Kuye R, Riggs C, King J, Heilmann R, Kurz D, Milchak J. Thyroid stimulating hormone stability in patients prescribed synthetic or desiccated thyroid products: a retrospective study. Ann Fam Med. 2020;18:452-454.
Toloza FJK, Espinoza Suarez NR, El Kawkgi O, et al. Patient experiences and perceptions associated with the use of desiccated thyroid extract. Medicina (Kaunas). 2020;56:161.
Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708-715.
Balestroni G, Bertolotti G. L'EuroQol-5D (EQ-5D): uno strumento per la misura della qualità della vita [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis. 2012;78:155-159.
Watt T, Cramon P, Hegedüs L, et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J Clin Endocrinol Metab. 2014;99:3708-3017.
Watt T, Bjorner JB, Groenvold M, et al. Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination. Qual Life Res. 2009;18:483-496.
Nordqvist SF, Boesen VB, Rasmussen ÅK, et al. Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO. Endocr Connect. 2021;10:316-324.
Coutinho J, Field JB, Sule AA. Armour® thyroid rage - a dangerous mixture. Cureus. 2018;10:e2523.
Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J Clin Endocrinol Metab. 2017;102:1623-1630.
Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623-1629.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24:1670-1751.
https://digital.nhs.uk/data-and-information/publications/statistical/practice-level-prescribing-data. Accessed December 31, 2020
Stedman M, Taylor P, Premawardhana L, Okosieme O, Dayan C, Heald AH. Trends in costs and prescribing for liothyronine and levothyroxine in England and wales 2011-2020. Clin Endocrinol. 2021;94(6):980-989.